Colorectal carcinoma
MONDO:0024331A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas.
Also known as: cancer of large bowel, cancer of large intestine, cancer of the large bowel, cancer of the large intestine, colorectal (colon or rectal) cancer, colorectal cancer, large bowel cancer, large intestine cancer
3992 clinical trials for this condition and its sub-types, 305 tagged with Colorectal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colorectal carcinoma
-
Colorectal adenocarcinoma 247 trials · 548 incl. sub-types
5 sub-types
- Rectum adenocarcinoma 232 trials · 233 incl. sub-types Sub-types →
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Colorectal serrated adenocarcinoma 1 trial
- Colorectal medullary carcinoma 0 trials Sub-types →
-
Rectal carcinoma 54 trials · 393 incl. sub-types
6 sub-types
- Rectum adenocarcinoma 232 trials · 233 incl. sub-types Sub-types →
- Anal carcinoma 85 trials · 129 incl. sub-types Sub-types →
- Squamous cell carcinoma of rectum 8 trials · 53 incl. sub-types Sub-types →
- Rectum carcinoma in situ 1 trial · 13 incl. sub-types Sub-types →
- Rectosigmoid carcinoma 5 trials
- Rectal sarcomatoid carcinoma 0 trials
-
Colon carcinoma 279 trials · 379 incl. sub-types
6 sub-types
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Cecum carcinoma 1 trial · 43 incl. sub-types Sub-types →
- Rectosigmoid carcinoma 5 trials
- Colon carcinoma in situ 3 trials Sub-types →
- Colon small cell neuroendocrine carcinoma 0 trials
- Squamous cell carcinoma of colon 0 trials Sub-types →
-
Colorectal squamous cell carcinoma 1 trial · 54 incl. sub-types
3 sub-types
- Squamous cell carcinoma of rectum 8 trials · 53 incl. sub-types Sub-types →
- Colorectal adenosquamous carcinoma 0 trials Sub-types →
- Squamous cell carcinoma of colon 0 trials Sub-types →
Most studied deeper sub-types
-
Could a vaccine stop colon cancer before it starts?
Vaccine OngoingThis study tests a vaccine that helps the body's immune system recognize and attack advanced colon polyps, which can turn into cancer. About 110 people who have had these polyps removed will receive either the vaccine or a placebo. The goal is to see if the vaccine boosts immune …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Vaccine
Last updated Sep 13, 2026 00:00 UTC
-
New vaccine aims to train immune system against lynch syndrome cancers
Vaccine OngoingThis study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, a genetic condition that raises the risk of colon and other cancers. The vaccine is made from man-made copies of proteins that cancer cells produce, aiming to teach the immune system to recognize and att…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC
-
New pill takes on rare salivary gland and colon cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…
Phase 1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cocktail aims to outsmart resistant colorectal cancer
Disease control OngoingThis early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for tough colon cancer: Triple-Drug attack shows promise
Disease control OngoingThis study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow t…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat colon cancer
Disease control PausedThis phase 2 trial is testing whether a combination of four drugs—BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab—can help control advanced colorectal cancer that has not responded to standard treatments. The study is for people with a specific type called microsat…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to boost immune system against tough cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest dose people can tolerate and to see if the drug helps the imm…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat GI cancers
Disease control OngoingThis trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control OngoingThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Phase 1/2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New triple therapy aims to shrink abdominal tumors in colorectal cancer
Disease control OngoingThis phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Stomach-Lining cancer: direct chemo attack
Disease control OngoingThis early-phase trial tests whether giving two standard chemotherapy drugs (5FU and oxaliplatin) directly into the abdominal cavity is safe for people with colorectal cancer that has spread only to the peritoneal lining. About 24 adults will receive the drugs through a catheter …
Phase 1 • Sponsor: Arjun Mittra • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Blood test could help pick the right drug for tough colorectal cancers
Disease control OngoingThis phase II trial is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose between two standard drugs—regorafenib or TAS-102—for people with advanced colorectal cancer that has stopped responding to other treatments. The study will enroll 100 par…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant colorectal cancer?
Disease control CancelledThis trial is testing whether combining two standard drugs—fruquintinib and TAS-102—can help people with metastatic colorectal cancer that has stopped responding to at least two prior chemotherapy regimens. The study will measure how long patients live without the disease getting…
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against tough cancers?
Disease control OngoingThis phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with or without radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with hig…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail aims to starve and attack tumors in advanced cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New pill takes on KRAS-Mutant cancers in early trial
Disease control OngoingThis early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Exercise after chemo: new trial tests if running and walking can keep colorectal cancer at bay
Disease control OngoingThis study tests whether a structured endurance exercise program, like walking or cycling, after finishing chemotherapy can help prevent colorectal cancer from returning. About 92 patients who have completed adjuvant chemotherapy will be randomly assigned to either an exercise pr…
Sponsor: Austrian Breast & Colorectal Cancer Study Group • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat colorectal cancer
Disease control OngoingThis study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo approach for Lung-Limited colorectal cancer shows promise in early trial
Disease control OngoingThis phase 2 trial studies whether combining chemotherapy with surgery to remove lung tumors works better than either treatment alone for patients with colorectal cancer that has spread only to the lungs. About 40 participants will be grouped by risk level to see if the combinati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug TPST-1495 tested in cancer patients before surgery
Disease control OngoingThis study tests a drug called TPST-1495 in people with endometrial or colorectal cancer who are scheduled for surgery. The drug aims to help the immune system fight cancer by blocking certain signals. Researchers will check blood and tumor samples before and after treatment to s…
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control OngoingThis early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Glowing dye could help surgeons spot hidden cancer during colorectal surgery
Disease control By invitation onlyThis trial investigates whether using a special dye called indocyanine green (ICG) during surgery helps improve outcomes for people with stage III colorectal cancer. The dye makes lymph nodes and cancer tissue glow under a special camera, helping surgeons see and remove more of t…
Sponsor: Shanghai Tong Ren Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill plus chemo shows promise for Hard-to-Treat colon cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug called onvansertib to standard chemotherapy and bevacizumab can shrink tumors better than chemo alone in people with advanced colorectal cancer that has a KRAS or NRAS mutation. About 110 participants who have not had p…
Phase 2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo attack targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy cocktail targets tough cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can control or shrink tumors in people with colorectal or pancreatic cancer that has specific genetic features (MSS or MSI-high). About 84 adults with advanced disease are…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Triple-Drug attack shows promise for tough colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…
Phase 1 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for advanced cancers: JANX008 enters human testing
Disease control OngoingThis early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: drug targets specific protein
Disease control OngoingThis phase 3 trial tests two different doses of an investigational drug called telisotuzumab adizutecan in about 74 adults with metastatic colorectal cancer that has stopped responding to standard treatments and whose tumors have a specific protein (c-Met). The drug is given by I…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy targets tough colorectal cancer
Disease control PausedThis study tests the safety and effectiveness of combining the experimental drug AVUTOMETINIB (VS-6766) with cetuximab in people with advanced colorectal cancer that has a KRAS mutation. It is for those whose cancer worsened after prior treatments or who cannot tolerate them. The…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Engineered immune cells take on Hard-to-Treat colorectal cancer
Disease control PausedThis early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have alre…
Early phase 1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Universal CAR-T therapy takes on advanced colorectal cancer
Disease control PausedThis early-phase trial tests a new universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side effects, w…
Early phase 1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Heat vs. scalpel: new study tests microwave ablation for lung cancer
Disease control OngoingThis study compares two standard treatments for lung tumors: microwave ablation, which uses heat to kill cancer cells, and surgical wedge resection, which removes a small piece of lung. Researchers want to see which method works better and is safer for patients with non-small cel…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody drug takes on advanced cancers in first human trial
Disease control OngoingThis early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …
Phase 1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants w…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cancer combo trial pulled before it even started
Disease control CancelledThis was a phase 2 study planned to test a new drug called NGM707 combined with the immunotherapy pembrolizumab in people with advanced or metastatic solid tumors, specifically colorectal cancer. The goal was to see if the combination could shrink tumors and to check for side eff…
Phase 2 • Sponsor: NGM Biopharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could chemo around surgery beat cancer spread in the belly?
Disease control OngoingThis study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…
Phase 2/3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Liver metastases showdown: radiation vs. microwave ablation in new trial
Disease control OngoingThis study compares two minimally invasive treatments—microwave ablation and stereotactic body radiation therapy—for colorectal cancer that has spread to the liver. About 100 patients with 1 to 3 liver tumors that cannot be surgically removed will be randomly assigned to one of t…
Phase 2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise for Hard-to-Treat gut cancers
Disease control OngoingThis study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Phase 1/2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Which chemo works best for advanced colon cancer? new study aims to find out
Disease control By invitation onlyThis study compares two chemotherapy treatments, FOLFOX-6 and CAPOX, in 248 adults aged 20-70 with metastatic colorectal cancer that has spread after surgery. The goal is to see which regimen better controls the disease and causes fewer side effects like liver problems or severe …
Sponsor: Allama Iqbal Medical College • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug duo shows promise for tough colorectal cancer
Disease control OngoingThis phase II trial is testing whether combining two drugs—niraparib and panitumumab—can help people with advanced colorectal cancer that has spread. The study includes 26 patients whose cancer has not responded to at least one prior treatment. The goal is to see if the combinati…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immune cell therapy trial for advanced cancers withdrawn before starting
Disease control CancelledThis early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Liver cancer patients get chemo via implantable pump in new safety trial
Disease control OngoingThis study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump i…
Sponsor: Ronald DeMatteo, M.D. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo aims to shrink Hard-to-Treat colon tumors
Disease control OngoingThis study tests a new drug, ABBV-400, combined with standard treatments for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 280 adults who have already tried one prior treatment will receive different doses of ABBV-400 plus chemothe…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …
Phase 1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 2 trial to test the drug CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug was designed to deliver a cancer-killing substance directly to tumor cells. However, the study was withdrawn before any …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Painkiller methadone joins chemo in fight against hard-to-treat colon cancer
Disease control OngoingThis early-phase trial tests whether adding the painkiller D,L-methadone to standard chemotherapy (mFOLFOX6) can help control advanced colorectal cancer that has stopped responding to other treatments. The study has two parts: first, finding a safe dose of methadone; second, comp…
Phase 1/2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Triple-Drug cocktail targets Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with a type of advanced colorectal cancer that has not responded to prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Cancer-Fighting T-Cell therapy trial for GI cancers withdrawn before start
Disease control CancelledThis study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
AI-Powered Low-Dose CT could spare cancer patients unnecessary radiation
Diagnosis OngoingThis study tests whether a low-radiation CT scan, enhanced with artificial intelligence software, can detect liver tumors as accurately as a standard CT scan. About 146 adults with colorectal cancer and known liver metastases will receive both scans. The goal is to see if the low…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New scan could spot hidden cancers
Diagnosis OngoingThis study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…
Early phase 1 • Sponsor: Julie L. Sutcliffe, Ph.D • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Can aspirin timing stop colon cancer?
Prevention OngoingThis study looks at whether taking aspirin in different patterns can help prevent colorectal cancer in people who have had colon polyps (adenomas). Aspirin may block certain enzymes that help cancer cells grow. The trial enrolled 81 adults with a history of colon polyps and measu…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Could a vaccine stop colon cancer in lynch syndrome patients?
Prevention OngoingThis phase IIb trial tests whether a vaccine called Tri-Ad5, combined with an immune booster N-803, can prevent colon cancer in people with Lynch syndrome. The vaccine targets proteins found in precancer and cancer cells, aiming to train the immune system to destroy them. 186 par…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Common antidepressant may shield cancer patients from chemo nerve damage
Prevention OngoingThis phase II/III trial tests whether duloxetine, a drug used for depression and pain, can prevent the nerve damage (pain, tingling, numbness) caused by oxaliplatin chemotherapy in stage II-III colorectal cancer patients. About 220 participants will receive either duloxetine or a…
Phase 2/3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Prevention
Last updated Jun 27, 2026 08:14 UTC
-
Cholesterol drug shows promise in preventing colon cancer for colitis patients
Prevention OngoingThis study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a per…
Phase 2 • Sponsor: Northwestern University • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
New program aims to close colorectal cancer screening gap for Low-Income and minority communities
Prevention OngoingThis study tests a culturally tailored program to increase colorectal cancer screening among low-income and ethnic minority groups, who are disproportionately affected by the disease. Nearly 10,000 patients aged 50-75 will receive education, consultations, and fecal immunochemica…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
Soy pretzels vs. wheat pretzels: a surprising weapon against inflammation?
Symptom relief OngoingThis study compares the effects of soy soft pretzels and wheat pretzels on inflammation in 30 men with obesity. Researchers want to see if the natural chemicals in soy can reduce chronic inflammation, which is linked to health problems like cancer. Participants will eat either so…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can acupuncture replace painkillers after surgery?
Symptom relief OngoingThis study looks at whether acupuncture can help manage pain after open abdominal surgery for colorectal or pancreatic cancer. About 70 patients will either receive acupuncture or standard care. The goal is to see if acupuncture reduces pain and the need for opioid painkillers, h…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Gut microbes may hold key to why cancer immunotherapy works for some
Knowledge-focused By invitation onlyResearchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New web tool aims to help cancer patients make sense of their genes
Knowledge-focused OngoingThis study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Blood test could decide who needs stronger or milder chemo for colorectal cancer
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative c…
Phase 3 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New program aims to close cancer knowledge gap in hispanic communities
Knowledge-focused OngoingThis study tests whether a training program for community specialists can help Hispanic/Latino adults learn more about colorectal cancer prevention and genetic testing. About 140 people from Los Angeles County will take part. The goal is to see if the program increases knowledge …
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused PausedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Phase 1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Personalized blood test aims to track stomach and colon cancer spread
Knowledge-focused PausedThis study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Blood test may spare thousands from unnecessary cancer surgery
Knowledge-focused OngoingThis study looks at whether a blood test that detects tumor DNA can accurately identify patients who still have cancer after local removal of early-stage colorectal cancer. Currently, many patients undergo additional surgery even though about 85% are already cured by the initial …
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New study seeks genetic clues to rising colorectal cancer in young adults
Knowledge-focused OngoingThis study investigates genetic factors that may increase the risk of developing colorectal cancer at a young age (18-50). Researchers will collect blood or saliva samples and review medical records from 818 participants, including patients and their family members. The goal is t…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New program aims to boost genetic testing awareness in Hispanic/Latino communities
Knowledge-focused OngoingThis study tests an educational program designed to train Hispanic/Latino community members about colorectal cancer genetics. The goal is to increase knowledge and confidence so they can educate others in their community. About 20 participants will attend weekly training sessions…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Simple blood tests could help monitor cancer treatment progress
Knowledge-focused OngoingThis study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Can a culturally tailored education boost cancer screening?
Knowledge-focused PausedThis study looks at what helps or hinders people from getting screened for colorectal cancer, focusing on African American, Latinx, and Chinese communities. Researchers will conduct interviews and focus groups to understand cultural beliefs and knowledge gaps. The goal is to crea…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Blood test may predict cancer recurrence in colorectal patients
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can help monitor for cancer recurrence in people with stage III colorectal cancer. Researchers will follow 137 participants over time to see if ctDNA levels relate to survival and whether they are better …
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC